Varicella Clinical Trial
Official title:
Tai Chi Chih and Varicella Zoster Immunity
A randomized control trial testing whether a relaxation response based intervention, Tai Chi Chih, will affect Varicella Zoster Virus (VZV) specific immunity measures of psychological adaptation and health function in the older adult.
Both the incidence and severity of Herpes Zoster (HZ) or "Shingles" increase markedly with
increasing age, is a painful condition, due to a decline in Varicella Zoster Virus (VZV)
specific immunity. Considerable evidence further shows that psychological stresses salient
in the older adult correlate with impairments of cellular immunity.
The investigators have observed that Varicella Zoster Immunity is always decreased in
individuals with major depression. Moreover, our preliminary data indicates that the
presence of depressive symptoms in older adults is associated with a decline of VZV
responder cell frequency (VZV-RCF). Taken together, the untoward effects of age and
depressive symptoms on VZV immunity raise the question as to whether an alternative medicine
intervention might augment VZV specific immunity in the older adult. We have preliminarily
shown that administration of a relaxation-response based intervention, Tai Chi Chih (TCC),
results in improvements in health functioning and VZV immunity in older adults as compared
to controls. TCC is a slow moving meditation comprised of twenty separate standardized
movements for use in elderly populations.
This proposed controlled clinical trial aims to: 1) determine whether the practice of TCC
for 16 weeks influences Varicella Zoster Virus (VZV) immunity; 2) demonstrate that TCC can
produce significant changes in psychological adaptation, health behaviors, and health
functioning and well-being; and 3) assess whether changes in psychological adaptation,
health behaviors, and health functioning correlate with changes in VZV immunity following
TCC in older adults.
We hypothesize that this behavioral intervention that prioritizes treatment of excessive
physiological arousal can influence one's affective state with effects on cellular immunity.
By standardization of training and practice schedules, TCC offers an important advantage
over prior relaxation response based therapies. Focus on older adults at increase risk for
HZ and assay of VZV specific cellular immunity has implications for understanding the impact
of behavioral factors and an alternative medicine intervention on a clinically relevant
endpoint and the ability of the immune system to respond to antigens of infectious
pathogens.
;
Allocation: Randomized
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00792623 -
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
|
Phase 2 | |
| Enrolling by invitation |
NCT05015686 -
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
|
Phase 3 | |
| Completed |
NCT00092430 -
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
|
Phase 3 | |
| Completed |
NCT00384397 -
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 3 | |
| Completed |
NCT00226499 -
Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox
|
Phase 3 | |
| Completed |
NCT00402831 -
ProQuad® Intramuscular vs Subcutaneous
|
Phase 3 | |
| Not yet recruiting |
NCT06068608 -
A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy
|
Phase 1 | |
| Completed |
NCT00560755 -
Safety Study of ProQuad® rHA in Infants (V221-037)
|
Phase 3 | |
| Completed |
NCT00715234 -
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
|
N/A | |
| Terminated |
NCT00258726 -
Immune Responses to Two Dose Varivax +/- MMR-II
|
Phase 1/Phase 2 | |
| Completed |
NCT03239873 -
Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
|
Phase 3 | |
| Completed |
NCT00751348 -
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
|
Phase 3 | |
| Completed |
NCT00969436 -
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
|
Phase 3 | |
| Completed |
NCT00566527 -
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
|
Phase 3 | |
| Completed |
NCT01390857 -
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
|
N/A | |
| Completed |
NCT00127010 -
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
|
Phase 3 | |
| Completed |
NCT00578175 -
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
|
Phase 2 | |
| Completed |
NCT00568334 -
Study of Two Formulations of GSK Biologicals' Varicella Vaccine
|
Phase 2 | |
| Completed |
NCT03114982 -
The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age
|
Phase 2 | |
| Completed |
NCT00483574 -
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
|
Phase 3 |